PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: WO 99/01117 (11) International Publication Number: **A3** A61K 31/35 (43) International Publication Date: 14 January 1999 (14.01.99) PCT/EP98/04066 (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, (21) International Application Number: BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, (22) International Filing Date: 1 July 1998 (01.07.98) GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, (30) Priority Data: ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), 1 July 1997 (01.07.97) RM97A000392 Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, (71) Applicant (for all designated States except US): CONSIGLIO BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). NAZIONALE DELLE RICERCHE [IT/IT]; Piazzale Aldo Moro, 7, I-00198 Rome (IT). Published (72) Inventors; and (75) Inventors/Applicants (for US only): SANTORO, Maria, Gabriella [IT/IT]; Via Vasto, 8, I-83100 Avellino (IT). With international search report. Before the expiration of the time limit for amending the claims ROSSI, Antonio [IT/IT]; Via Orientale, 33, I-66010 and to be republished in the event of the receipt of amendments. Colledimacine (IT). ELIA, Giuliano [IT/IT]; Via della Stella, 321, I-00036 Palestrina (IT). (88) Date of publication of the international search report: 1 April 1999 (01.04.99) (74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi, Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(54) Title: INHIBITORS OF NF-KAPPAB AS ACTIVATORS OF HSF AND INDUCERS OF HEAT SHOCK PROTEINS

(57) Abstract

Inhibitors of the NF-kB factor and corresponding pharmaceutically acceptable derivative compounds to be used as activators of the HSF factor for the transcription and translation of heat shock genes, with production of hsp70, particularly with anti-inflammatory, anti-proliferative, immuno-suppressive, cytoprotective and antiviral activity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

\mathbf{AL}	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
\mathbf{AM}	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	\mathbf{UG}	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	$\mathbf{U}\mathbf{Z}$	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	\mathbf{PL}	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	$\mathbf{s}\mathbf{G}$	Singapore		

In' itional Application No PCT/EP 98/04066

A. CLASS IPC 6	ification of subject matter A61K31/35		<u>-</u>
According t	to International Patent Classification (IPC) or to both national classific	cation and IPC	
	SEARCHED		
	ocumentation searched (classification system followed by classificat	ion symbols)	
IPC 6	A61K	ion symbolog	
Documenta	ation searched other than minimum documentation to the extent that s	such documents are included in the fields s	earched
Electronic	data base consulted during the international search (name of data ba	ase and, where practical, search terms used	4)
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the re-	lovent nagonage	Deleverate aleier Ne
Calegory	Citation of document, with indication, where appropriate, or the re	levant passages	Relevant to claim No.
X	ROSSI A ET AL: "INHIBITION OF NU FACTOR KB BY PROSTAGLANDIN A1: AI ASSOCIATED WITH HEAT SHOCK TRANSOF FACTOR ACTIVATION" PROCEEDINGS OF THE NATIONAL ACADESCIENCES OF USA, vol. 94, no. 2, 21 January 1997, 746-750, XP002069382 see abstract see "results and discussion" see figures 4,5	N EFFECT CRIPTION EMY OF	1,2,5-12
X Furth	her documents are listed in the continuation of box C.	X Patent family members are listed	in annex.
° Special ca	tegories of cited documents :		
"A" docume	ent defining the general state of the art which is not	"T" later document published after the inte or priority date and not in conflict with	the application but
consid	lered to be of particular relevance	cited to understand the principle or the invention	
"E" earlier o	document but published on or after the international late	"X" document of particular relevance; the c	laimed invention
"L" docume	nate ant which may throw doubts on priority claim(s) or is cited to establish the publication date of another	cannot be considered novel or cannot involve an inventive step when the do	be considered to cument is taken alone
citation	n or other special reason (as specified)	"Y" document of particular relevance; the c cannot be considered to involve an involve an involve and	laimed invention
"O" docume other r	ent referring to an oral disclosure, use, exhibition or means	document is combined with one or mo ments, such combination being obvious	ore other such docu-
"P" docume	ent published prior to the international filling date but han the priority date claimed	in the art. "&" document member of the same patent	·
	actual completion of the international search	Date of mailing of the international sea	
	February 1999	18/02/1999	iion report
Name and n	nailing address of the ISA	Authorized officer	
	European Patent Office, P.B. 5818 Patentlaan 2	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,	A. Jakobs	
	Fax: (+31-70) 340-3016	A. Jakobs	

3

In Itional Application No
PCT/EP 98/04066

C (C	NI> DOCUMENTO CONOIDED-	PC1/EP 98/04066
Category :	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAGAWA, HIDEO ET AL: "Effect of proteinase inhibitors having antiinflammatory activity on gelatinase, elastase, and cathepsin G isolated from rat polymorphonuclear leukocytes" J. PHARMACOBIO-DYN. (1982), 5(5), 319-27 CODEN: JOPHDQ; ISSN: 0386-846X, XP002091952 see abstract see page 326, column 1, line 10-17	1
X	BREITHAUPT T B ET AL: "The suppression of T cell function and NF (kappa) B expression by serine protease inhibitors is blocked by N-acetylcysteine." CELLULAR IMMUNOLOGY, (1996 OCT 10) 173 (1) 124-30. JOURNAL CODE: CQ9. ISSN: 0008-8749., XP002091953 United States see abstract	
X	AMICI ET AL.: "Selective Inhibition of Virus Protein Synthesis by Prostaglandin Al: a Translational Block Associated with HSP70 Synthesis." J. VIROL., vol. 68, 1994, pages 6890-6899, XP002091954 see abstract	1
X	FINCO ET AL.: "Inducible phosphorylation of IkappaBalpha is not sufficient for its dissociation from NF-kappaB and is inhibited by protease inhibitors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, XP002091955 see abstract see page 11884, column 1 - column 2; figure 1 see page 11888, column 1, paragraph 2-4	1-3,8,9, 11,13-15
X	YANG X ET AL: "Proteinases in renal cell death." JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, (1996 JUL) 48 (4) 319-32. JOURNAL CODE: KAA. ISSN: 0098-4108., XP002091956 United States see abstract see page 322, paragraph 3 see page 323, paragraph 2-3; figure 3 -/	1-3,5,8, 9,11, 13-15

In' itional Application No
PCT/EP 98/04066

		PCT/EP 98/04066
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUESDON F ET AL: "Interleukin 1-induced phosphorylation of MAD3, the major inhibitor of nuclear factor kappa B of HeLa cells. Interference in signalling by the proteinase inhibitors 3,4-dichloroisocoumarin and tosylphenylalanyl chloromethylketone." BIOCHEMICAL JOURNAL, (1995 APR 1) 307 (PT 1) 287-95. JOURNAL CODE: 9YO. ISSN: 0264-6021., XP002091957 ENGLAND: United Kingdom see abstract see page 287, column 1, paragraph 1 see page 291, column 2, paragraph 5 - page 293, column 1, paragraph 3; figure 6 see page 294, column 2, paragraph 2	1-3,5,8, 9,11, 13-15
X	US 4 954 519 A (POWERS JAMES C ET AL) 4 September 1990 see abstract	1-3,5,8, 9,11, 13-15
	see column 1, line 19-31 see column 2, line 66 - column 3, line 11; tables 6,7	
X	DE 43 11 835 A (BOEHRINGER INGELHEIM INT) 13 October 1994 see column 12, line 64 - column 13, line 9; claims 1-9; examples 4,6	1-14
X	ZHIRNOV, O. P. ET AL: "Alphavirus replication in cultured cells and infected animals is inhibited by antiproteinase agents" ANTIVIRAL RES. (1986), 6(5), 255-65 CODEN: ARSRDR; ISSN: 0166-3542, XP002092229 see abstract	1-3,5-14
X	CHEN F ET AL: "Dependence and reversal of nitric oxide production on NF - kappa B in silica and lipopolysaccharide-induced macrophages." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1995 SEP 25) 214 (3) 839-46. JOURNAL CODE: 9Y8. ISSN: 0006-291X., XP002092230 United States see abstract see page 840, paragraph 2; figure 3 see page 844, paragraph 2 - page 845, paragraph 2	1-3,5,8, 9,11,13, 14

int tional Application No
PCT/EP 98/04066

		FC1/EP 98/04000
C.(Continu	Ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
	app. op. and app.	reference didning.
X	DENKO, NICHOLAS C. ET AL: "Protease inhibitor TPCK represses Ha-ras (Vall2) transformation and nuclear factorkappa. B activation" INT. J. ONCOL. (1997), 10(5), 895-900 CODEN: IJONES; ISSN: 1019-6439, XP002092231 see abstract	1-3,5,8, 9,11-14
X	SCHNEBLI H P: "GROWTH INHIBITION OF TUMOR CELLS BY PROTEASE INHIBITORS CONSIDERATION OF THE MECHANISMS INVOLVED." CLARKSON, BAYARD AND RENATO BASERGA (ED.). COLD SPRING HARBOR CONFERENCES ON CELL PROLIFERATION, VOL. 1. CONTROL OF PROLIFERATION IN ANIMAL CELLS. XIII+1029P. ILLUS. COLD SPRING HARBOR LABORATORY: PO BOX 100, COLD SPRING HARBOR, N.Y. 11724, U.S.A. (1, XP002092232 see abstract; table 4	1-3,5,8, 9,11,13, 14
X	WU, MIN ET AL: "Inhibition of NF kappa. B /Rel induces apoptosis of murine B cells" EMBO J. (1996), 15(17), 4682-4690 CODEN: EMJODG; ISSN: 0261-4189, XP002092233 see abstract	1-3,5,8, 9,13,14
X	CONANT K ET AL: "Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF - kappa B binding and protein kinase C activity in primary human astrocytes." JOURNAL OF VIROLOGY, (1996 MAR) 70 (3) 1384-9. JOURNAL CODE: KCV. ISSN: 0022-538X., XP002092234 United States see abstract see page 1386, column 1, paragraph 2 - column 2, paragraph 2	1-3,5-14

3

cernational application No.

PCT/EP 98/04066

Box I Observations where certain	n claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not l	been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject m	natter not required to be searched by this Authority, namely:
an extent that no meaningful inte	ne International Application that do not comply with the prescribed requirements to such ernational Search can be carried out, specifically: TION SHEET PCT/ISA/210
Claims Nos.: because they are dependent clair	ims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of	of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority four	nd multiple inventions in this international application, as follows:
As all required additional search searchable claims.	fees were timely paid by the applicant, this International Search Report covers all
2. As all searchable claims could be of any additional fee.	e searched without effort justifying an additional fee, this Authority did not invitepayment
3. As only some of the required add covers only those claims for which	ditional search fees were timely paid by the applicant, this International Search Report the fees were paid, specifically claims Nos.:
No required additional search fee restricted to the invention first me	es were timely paid by the applicant. Consequently, this International Search Report is entioned in the claims; it is covered by claims Nos.:
Remark on Protest	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In view of the large number of compounds, which are defined by the general definition(s)/formulae used in claims 1-2, 5-12, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application. (See Guidelines, chapter III, paragraph 2.3).

Regarding claims 3, 13 and 14: "N-benzoyl-L-Thyroxine-ethylester" was considered to be an obvious error and regarded as intended to mean "N-benzoyl-L-Tyrosine-ethylester (BTEE)" as apparent from the description, and searched a ssuch.

Information on patent family members

Int :tional Application No PCT/EP 98/04066

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4954519 A	04-09-1990	US 4845242 A US 5089633 A US 5089634 A US 5324648 A	04-07-1989 18-02-1992 18-02-1992 28-06-1994
DE 4311835 A	13-10-1994	AU 691492 B AU 6538094 A CA 2159822 A WO 9423045 A EP 0693129 A JP 8508169 T	21-05-1998 24-10-1994 13-10-1994 13-10-1994 24-01-1996 03-09-1996